41 related articles for article (PubMed ID: 9665302)
1. Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection.
Hung YP; Lee JC; Lin HJ; Liu HC; Wu YH; Tsai PJ; Ko WC
Antibiotics (Basel); 2015 Jun; 4(2):216-29. PubMed ID: 27025622
[TBL] [Abstract][Full Text] [Related]
2. The potential for emerging therapeutic options for Clostridium difficile infection.
Mathur H; Rea MC; Cotter PD; Ross RP; Hill C
Gut Microbes; 2014; 5(6):696-710. PubMed ID: 25564777
[TBL] [Abstract][Full Text] [Related]
3. Future novel therapeutic agents for Clostridium difficile infection.
Koo HL; Garey KW; Dupont HL
Expert Opin Investig Drugs; 2010 Jul; 19(7):825-36. PubMed ID: 20521993
[TBL] [Abstract][Full Text] [Related]
4. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.
Shah D; Dang MD; Hasbun R; Koo HL; Jiang ZD; DuPont HL; Garey KW
Expert Rev Anti Infect Ther; 2010 May; 8(5):555-64. PubMed ID: 20455684
[TBL] [Abstract][Full Text] [Related]
5. Moxifloxacin in the treatment of skin and skin structure infections.
Guay DR
Ther Clin Risk Manag; 2006 Dec; 2(4):417-34. PubMed ID: 18360653
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.
Goldstein EJ; Citron DM; Warren YA; Tyrrell KL; Merriam CV; Fernandez H
Antimicrob Agents Chemother; 2006 Jan; 50(1):148-55. PubMed ID: 16377680
[TBL] [Abstract][Full Text] [Related]
7. gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.
Dridi L; Tankovic J; Burghoffer B; Barbut F; Petit JC
Antimicrob Agents Chemother; 2002 Nov; 46(11):3418-21. PubMed ID: 12384345
[TBL] [Abstract][Full Text] [Related]
8. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
9. Susceptibilities of Propionibacterium acnes ophthalmic isolates to moxifloxacin.
Dali P; Giugliano ER; Vellozzi EM; Smith MA
Antimicrob Agents Chemother; 2001 Oct; 45(10):2969-70. PubMed ID: 11583007
[No Abstract] [Full Text] [Related]
10. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA.
Ackermann G; Tang YJ; Kueper R; Heisig P; Rodloff AC; Silva J; Cohen SH
Antimicrob Agents Chemother; 2001 Aug; 45(8):2348-53. PubMed ID: 11451695
[TBL] [Abstract][Full Text] [Related]
11. Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents.
Betriu C; Gómez M; Palau ML; Sánchez A; Picazo JJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2320-2. PubMed ID: 10471590
[TBL] [Abstract][Full Text] [Related]
12. Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.
Nord CE
Infection; 1999; 27(3):166-72. PubMed ID: 10378126
[No Abstract] [Full Text] [Related]
13. Moxifloxacin.
Balfour JA; Wiseman LR
Drugs; 1999 Mar; 57(3):363-73; discussion 374. PubMed ID: 10193688
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro activity of BAY 12-8039 and five other antimicrobial agents against anaerobic bacteria.
Edlund C; Sabouri S; Nord CE
Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):193-5. PubMed ID: 9665302
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of BAY y 3118, and nine other antimicrobial agents against anaerobic bacteria.
García-Rodríguez JA; García-Sánchez JE; Trujillano-Martín I; García-Sánchez E; García-García MI; Fresnadillo-Martínez MJ
J Chemother; 1995 Jun; 7(3):189-96. PubMed ID: 7562012
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
Nord CE
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
[TBL] [Abstract][Full Text] [Related]
18. Resistance of anaerobic bacteria to antimicrobial agents in Spain.
Baquero F; Reig M
Eur J Clin Microbiol Infect Dis; 1992 Nov; 11(11):1016-20. PubMed ID: 1295754
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of imipenem against anaerobic bacteria.
Wexler HM; Finegold SM
Rev Infect Dis; 1985; 7 Suppl 3():S417-25. PubMed ID: 3901206
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
